U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment:: https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646

Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

146102400000
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

146102400000
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

146102400000
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

146102400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.7 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEPHRADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
27.5 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEPHRADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.61 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEPHRADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Capillary electrophoresis study on the micellization and critical micelle concentration of sodium dodecyl sulfate. Influence of solubilized solutes.
2001 Jul 27
Effect of UV-B radiation on some common antibiotics.
2002 Apr
Clinical significance and epidemiology of NO-1, an unusual bacterium associated with dog and cat bites.
2002 Feb
Transport and utilization of arginine and arginine-containing peptides by rat alveolar macrophages.
2002 Jun
Prolonged intestinal absorption of cephradine with chitosan-coated ethylcellulose microparticles in rats.
2002 Nov
A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference.
2003 Apr
Sensitive determination of a beta-lactam antibiotic, cefaclor by liquid chromatography with chemiluminescence detection.
2003 Jan 15
Symphyseal diastasis and vestibular rupture during spontaneous vaginal delivery.
2003 Jun
Treatment of breast abscesses with sonographically guided aspiration, irrigation, and instillation of antibiotics.
2003 Oct
Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol.
2003 Sep
Microbiology and drug sensitivity patterns of chronic suppurative otitis media.
2004 Aug
Preparation and characterization of porous hollow silica nanoparticles for drug delivery application.
2004 Feb
Re: "Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol" Solis et al. (Pediatr Pulmonol 2003;36: 189-195).
2004 Sep
Purification and characterization of inducible cephalexin synthesizing enzyme in Gluconobacter oxydans.
2005 Mar
Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection.
2005 Oct 21
Properties and active substance release kinetics from gelatin-alginate matrices.
2006
Crystal form of cephradine.
2006 Feb
Controlled drug delivery system based on magnetic hollow spheres/polyelectrolyte multilayer core-shell structure.
2006 Sep-Oct
Characterization of beta-lactamases from urinary isolates of Escherichia coli in Tehran.
2007 Apr
Determination of beta-lactam antibiotics in milk using micro-flow chemiluminescence system with on-line solid phase extraction.
2007 Jun 5
Use of SDS micelles for improving sensitivity, resolution, and speed in the analysis of beta-lactam antibiotics in environmental waters by SPE and CE.
2007 Sep
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.
2008 Aug
Effects of treatment with antimicrobial agents on the human colonic microflora.
2008 Dec
Human case of Rickettsia felis infection, Taiwan.
2008 Dec
Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever.
2008 Dec
[Prophylactic use of antibiotics in selective colorectal operation: a randomized controlled trial].
2008 Jan 15
Pharmacokinetic study of cephradine in Pakistani healthy male volunteers.
2008 Oct
Studies on diseased freshwater prawn Macrobrachium rosenbergii infected with Vibrio vulnificus.
2008 Sep 1
Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations.
2009
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes.
2009
A study of the chemiluminescence behavior of cephalosporins with luminol and its analytical application.
2009 Aug
[Analysis of multiple cephalosporins in blood and urine by HPLC].
2009 Dec
Rapid and simple method for determination of cephradine in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS): application to the bioequivalence study.
2009 Dec 1
Antibiotics for mastitis in breastfeeding women.
2009 Jan 21
Lack of interaction between the peptidomimetic substrates captopril and cephradine.
2009 Mar
Traumatic optic neuropathy accompanying orbital grease gun injury.
2010 Apr
Colorimetric detection of cephradine in pharmaceutical formulations via fluorosurfactant-capped gold nanoparticles.
2010 Apr 15
Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns.
2010 Jan
Selective densitometric determination of four alpha-aminocephalosporins using ninhydrin reagent.
2010 Jan
Uropathogen resistance to antibiotic prophylaxis in urinary tract infections.
2010 Jun
Rate of conversion and complications of laparoscopic cholecystectomy in a tertiary care center in Saudi Arabia.
2010 Mar-Apr
Patents

Sample Use Guides

For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours.
Route of Administration: Oral
In Vitro Use Guide
Sources: DOI: 10.5897/IJPS11.057
MIC 90 of Cephradine standard powder against 25 clinical isolates of S. aureus was 2048 ug/ml.
Substance Class Mixture
Created
by admin
on Fri Jun 25 20:52:02 UTC 2021
Edited
by admin
on Fri Jun 25 20:52:02 UTC 2021
Record UNII
F1BC02I72W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEPHRADINE
ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
VELOSEF
Brand Name English
CEPHRADINE HYDRATE [MART.]
Common Name English
CEPHRADINE [USP-RS]
Common Name English
CEFRADINE HYDRATE
Common Name English
CEPHRADINE [VANDF]
Common Name English
SK&F-D-39304
Code English
SQ-11436
Code English
SQ-22022
Code English
CEPHRADINE [USP MONOGRAPH]
Common Name English
ANSPOR
Brand Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(2-AMINO-2-(1,4-CYCLOHEXADIEN-1-YL)ACETAMIDO)-3-METHYL-8-OXO-, HYDRATE, D-
Common Name English
CEPHRADINE NON-STOICHIOMETRIC HYDRATE FORM
Common Name English
SQ 11436
Code English
CEPHRADINE, UNSPECIFIED HYDRATE
Common Name English
CEPHRADINE [ORANGE BOOK]
Common Name English
CEPHRADINE [USAN]
Common Name English
CEPHRADINE HYDRATE
MART.  
Common Name English
SK&F D-39304
Code English
Classification Tree Code System Code
WHO-ATC J01DB09
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
NCI_THESAURUS C357
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
LIVERTOX 178
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
NDF-RT N0000175488
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C47441
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
EVMPD
SUB21808
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
MESH
D002515
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
ChEMBL
CHEMBL1604
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
FDA UNII
F1BC02I72W
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
USP_CATALOG
1102805
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY USP-RS
EVMPD
SUB07417MIG
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
IUPHAR
4830
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
RXCUI
2239
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY RxNorm
LACTMED
Cephradine
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Definition References